Canagliflozin
Canagliflozin is an inhibitor of sodium glucose co-transporter 2 (SGLT2), the transporter responsible for reabsorbing the majority of glucose filtered by the kidney.It is chemically known as (1S)-1,5-anhydro-1-[3-[[5- (4-fluorophenyl) 2 thienyl]methyl]-4-methylphenyl]-D glucitol hemihydrate. Canagliflozin is used as an adjunct to diet and exercise to improve glycemic control in adult with Type 2 Diabetics Mellitus
Primary Characteristics
It is of Synthetic origin and belongs to C- Glycosyl.
Molecular Weight: 453.53 · Solubility in Water: insouble · Non-proprietary name: Canagliflozin.
Pharmacokinetics
Absorption: Canagliflozin has an oral bioavailability is 65%.
Distribution: Canagliflozin has a volume of distribution is 119L. plasma protein binding is 99%.
Elimination: it is metabolised via hepatic, plasma half-life is 10.6 - 13.1 h, renal excretion is 33% by urine , 41 % by feces.
Advertisement
Indications
Canagliflozin is primarily indicated in conditions like Type II diabetes mellitus.
Contraindications
None recorded.
Dosage
Canagliflozin's dosage details are as follows:
| Dose | Single Dose | Frequency | Route | Instructions |
|---|---|---|---|---|
| Adult Dosage | ||||
| 0 – 100 mg | — | Every 1h | PO | taken before the first meal of the day |
| 300 mg | 300 mg | Every 1h | PO | with eGFR of 60 mL/min/1.73 m2 or greater and require additional glycemic control |
| Paediatric Dosage (20kg) | ||||
| No data. | ||||
| Neonatal Dosage (3kg) | ||||
| No data. | ||||
Drug Interactions
Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Side Effects
Canagliflozin is known to cause more or less tolerable side effects which are usually transient. These include female genital mycotic infections, increased urination, urinary tract infection.
Warnings / Precautions
Available Brands
None recorded.
Storage Conditions
Drug Classification
- 1.18.7.2 — Oral hypoglycemics